Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
Holding VYNE?
Track your performance easily
VYNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.57 - $6.79
Previous Close$2.14
Volume143.67K
Average Volume (3M)54.40K
Market Cap
$31.09M
Enterprise Value-$54.68M
Total Cash (Recent Filing)$85.95M
Total Debt (Recent Filing)$180.00K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 09, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.42
Shares Outstanding14,528,247
10 Day Avg. Volume98,062
30 Day Avg. Volume54,403
Standard Deviation0.25
R-Squared0.08
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.30
Price to Sales (P/S)62.36
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-129.27
Enterprise Value/Gross Profit-136.70
Enterprise Value/Ebitda1.80
Forecast
1Y Price Target
$5.88Price Target Upside161.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
VYNE Therapeutics News
PremiumCompany Announcements
VYNE Therapeutics Sees Strong Shareholder Support for Growth
PremiumCompany Announcements
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024
Bulls Say, Bears Say
Bulls Say
Clinical DataVYN201 has demonstrated similar or greater improvements in F-VASI compared to JAK inhibitors at an earlier timepoint.
Clinical TrialsThe first patient has been dosed in the Phase 2b vitiligo study assessing VYN201, based on encouraging safety and efficacy results from Phase 1b trials.
Treatment PotentialThe 3% concentration of VYN201 has the potential to show improved efficacy compared to lower doses while remaining well-tolerated due to its limited systemic exposure.
Bears Say
Drug SafetyPrevious systemic BET inhibitors have been associated with thrombocytopenia and gastrointestinal toxicities.
EarningsVYNE announced results, posting EPS of ($0.15).
TherapiesThere is still a significant unmet need for novel therapies that have a faster onset of action, are less burdensome for patients, and have an improved safety profile without a black box warning.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $1.57 and its highest was $6.79 in the past 12 months.
What is VYNE Therapeutics’s market cap?
Currently, no data Available
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is Aug 09, 2024 which is 134 days ago.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on May 09, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.09.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 14,528,247 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -2.574%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Among the largest hedge funds holding VYNE Therapeutics’s share is Perceptive Advisors LLC. It holds VYNE Therapeutics’s shares valued at N/A.
---
VYNE Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.88 (161.33% Upside)
$5.88 (161.33% Upside)
Hedge Fund Trend
Decreased
By 121.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.76%
12-Months-Change
Fundamentals
Return on Equity
-51.92%
Trailing 12-Months
Asset Growth
159.98%
Trailing 12-Months
Company Description
VYNE Therapeutics
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
---
VYNE Stock 12 Month Forecast
Average Price Target
$5.88
▲(161.33% Upside)
Technical Analysis
Best Analysts Covering VYNE
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-28.70%
reiterated a buy rating 6 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -28.70% per trade.
---